FGF 23 clearance in haemodialysis patients Urological and Genital Diseases
Conditions
Interventions
This study will include adult patients with renal failure who are on long term haemodialysis (HD). During this study, patients will be randomized (using sealed envelope) to one week monitored HD trea
Sponsors
Salford Royal NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and over 2. End stage renal failure 3. On regular haemodialysis
Exclusion criteria
Exclusion criteria: 1. Lack of capacity to consent to treatment 2. Significant residual urine output (> 500 ml of urine per 24 hours) 3. Poor dialysis adequacy (urea reduction ratio < 65%) 4. Active infection 5. Active malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FGF 23 clearance measured using blood test before and after receiving dialysis for one week with each type of membrane | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using blood test before and after receiving dialysis for one week with each type of membrane: 1. Stability of FGF 23 clearance 2. Rate of FGF 23 re-accumulation 3. Phosphate, calcium and urea clearance and PTH levels 4. Range of circulating proteins measured using whole proteome analysis | — |
Countries
England, United Kingdom
Outcome results
None listed